Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02124876 · ClinicalTrials.gov registry record

Accommodating for Residual Limb Fluid Volume Change

A clinical trial, sponsored by University of Washington.

Completed
Registry status
45
Enrollment target

NCT02124876: Completed study, sponsored by University of Washington.

NCT02124876 is a clinical trial that has completed, run by University of Washington. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02124876 has completed, sponsored by University of Washington.

COMPLETED
Registry status
45 participants
Enrollment target

Study Summary

The purpose of this study is to quantify residual limb fluid volume changes between morning and afternoon hours, and to determine if fluid volume change is correlated with activity.

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2013-06
Est. Completion 2014-06-06
University of Washington

1,048 total trials

What the finished NCT02124876 record still lists

NCT02124876 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT02124876 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02124876 about?

NCT02124876 is a clinical study titled "Accommodating for Residual Limb Fluid Volume Change". The purpose of this study is to quantify residual limb fluid volume changes between morning and afternoon hours, and to determine if fluid volume change is correlated with activity.

What is the current status of trial NCT02124876?

This trial is currently completed. The enrollment target is 45 participants. The study started on 2013-06. Estimated completion is 2014-06-06.

Who is sponsoring clinical trial NCT02124876?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02124876, the US trial registry maintained by the National Library of Medicine. NCT02124876 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.